Compositions and methods for inhibiting the proliferation of pathogenic Escherichia coli
Inventors
Yoon, Seong Jun • Son, Jee Soo • KIM, In Hwang • Paik, Hyoung Rok • IM, Hyun Joo • Park, Ji Young • YU, Hyun Jin • SEO, Ji Yeong • JUN, Soo Youn • Kang, Sang Hyeon
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11583565-B2
Publication Date
2023-02-21
Expiration Date
Abstract
A composition for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes a Myoviridae bacteriophage having an ability to lyse the pathogenic Escherichia coli and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by a pathogenic Escherichia coli includes administering to a subject a Myoviridae bacteriophage and lysing the pathogenic Escherichia coli by the Myoviridae bacteriophage.
Core Innovation
The invention relates to a composition for preventing or treating an infection or disease caused by a pathogenic Escherichia coli. The composition comprises a Myoviridae bacteriophage Esc-COP-15 that has an ability to lyse the pathogenic Escherichia coli and a genome represented by a sequence set forth in SEQ ID NO: 1. The Esc-COP-15 is described as having been deposited in the Korean Collection for Type Cultures (KCTC) under accession number KCTC 14027BP.
The composition is characterized by specific lytic properties and dosing concentration ranges. The Esc-COP-15 has a latent period of 20-70 minutes and a burst size of 80-200 plaque-forming units (PFU)/infected cell, and is used at a concentration of 1×10^4 PFU/ml to 1×10^15 PFU/ml or 1×10^4 PFU/g to 1×10^15 PFU/g, together with a pharmaceutically acceptable carrier.
The documented description further frames the targeted pathogenic Escherichia coli and the intended disease outcomes. The composition is associated with specific Escherichia coli pathotypes and disease settings, and includes characterization and efficacy data in piglet and mouse models as well as in vitro growth inhibition. The description also addresses optional inclusion of carriers/excipients and a second bacteriophage capable of lysing a broader bacterial target.
Claims Coverage
The independent claim covers one inventive concept: an anti-pathogenic Escherichia coli composition based on the specific Myoviridae bacteriophage Esc-COP-15, formulated with a pharmaceutically acceptable carrier, with specified latent period, burst size, and concentration range.
Esc-COP-15 defined by SEQ ID NO: 1 and KCTC deposit
A composition comprising a Myoviridae bacteriophage Esc-COP-15 having an ability to lyse the pathogenic Escherichia coli and a genome represented by a sequence set forth in SEQ ID NO: 1, wherein the Myoviridae bacteriophage Esc-COP-15 has been deposited in the Korean Collection for Type Cultures (KCTC) under accession number KCTC 14027BP.
Lytic performance parameters for Esc-COP-15
The Myoviridae bacteriophage Esc-COP-15 has a latent period of 20-70 minutes and a burst size of 80-200 plaque-forming units (PFU)/infected cell.
Defined Esc-COP-15 concentration in a carrier formulation
The composition further comprises a pharmaceutically acceptable carrier and wherein the Myoviridae bacteriophage Esc-COP-15 has a concentration of 1×10^4 PFU/ml to 1×10^15 PFU/ml or 1×10^4 PFU/g to 1×10^15 PFU/g.
Overall, the claim coverage centers on a specific lyse-capable Myoviridae bacteriophage, Esc-COP-15, defined by SEQ ID NO: 1 and a KCTC accession, used with specified latent period and burst size, and formulated with a pharmaceutically acceptable carrier at a defined PFU concentration range.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?